Pathway link EVE-BREAST
Everolimus Breast cancer
Everolimus inhibits Breast cancer.
Adding everolimus to hormone therapy roughly doubled the time before certain advanced breast cancers got worse.
The conditions it holds under
Progression-free survival, in combination with exemestane - overall survival was not significantly improved.
- Time it takes
- long exposure (days to weeks)
- Step
- indirect (through steps not drawn here)
- Measured in
- human
- Reaches people?
- shown in people
- How settled
- settled in the literature
Studies behind it
| Year | Evidence | Study |
|---|---|---|
| 2012 | H | Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer (BOLERO-2)BAS2012 A phase 3 RCT (n=724) proving mTOR matters in a common cancer. Resistance to hormone therapy in breast cancer is associated with mTOR activation. Adding everolimus more than doubled progression-free survival (10.6 vs 4.1 months by central review) - leading to FDA approval. Main toxicity was stomatitis. |
| 2014 | H | Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†PIC2014 This is the final overall-survival report of BOLERO-2, the phase III double-blind trial (published primary analysis: BAS2012) in which postmenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer that had progressed on a nonsteroidal aromatase inhibitor received exemestane 25 mg/day plus either everolimus 10 mg/day or placebo. The primary endpoint, progression-free survival by local investigator, remained improved: median 7.8 vs 3.2 months (P < 0.0001), a 4.6-month gain. Overall survival, a key secondary endpoint, was not significantly improved: median 31.0 vs 26.6 months, hazard ratio 0.89 (95% CI 0.73-1.10), P = 0.14, at 410 deaths. Most patients went on to further treatment after the trial (84% vs 90%), with less chemotherapy in the everolimus arm (53% vs 63%), which may have diluted any survival difference. No new safety concerns were identified. Boundary: postmenopausal women with HR+/HER2- advanced breast cancer previously treated with a nonsteroidal aromatase inhibitor; comparator was exemestane plus placebo; the survival benefit of adding mTOR inhibition was not shown. |
Points the other way
No study in the Atlas contradicts this link. That means none in this curated set, not none in the literature.
Who has checked this
- Checked by
- No researcher outside the project has checked this link yet.
- Curator sign-off
- Not signed off yet. This link was drafted with AI help and has not been reviewed link by link; treat it as a proposal until it is.
- Curated by
- Oliver Barton, with AI help for drafting; see how links are checked.
← The whole pathway · This link as JSON
Was this page useful?
Thank you. Your answer was counted anonymously.
Spotted something wrong or out of date about this link?
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.